Design and screening strategies for α-Glucosidase inhibitors based on enzymological information

Current Topics in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 3-12

  Hakamata, Wataru ^a,c   Kurihara, Masaaki ^b   Okuda, Haruhiro ^b   Nishio, Toshiyuki ^a   Oku, Tadatake ^a  

^a NIHON UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c NONE   (Japan)

Author keywords

HTS; In silico; Inhibitor; Structure based drug design; Substrate specificity; Virtual screening; Glucosidase

Indexed keywords

1 DEOXYNOJIRIMYCIN; ACARBOSE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ASPARAGINE LINKED OLIGOSACCHARIDE; CARBOHYDRATE; GLYCOSIDASE INHIBITOR; KOJIBIOSE; MIGLITOL; NOJIRIMYCIN; UNCLASSIFIED DRUG; VOGLIBOSE; ZANAMIVIR;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CARBOHYDRATE METABOLISM; COMPUTER AIDED DESIGN; COMPUTER MODEL; DIABETES MELLITUS; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; INFLUENZA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REACTION ANALYSIS; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; VIRTUAL REALITY;

EID: 63249112782     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609787354306     Document Type: Review

References (112)

1. Consult http://www.cazy.org/CAZY/ for further information.
2. Coutinho, P. M.; Henrissat, B. Carbohydrate-Active Enzymes: An Integrated Approach. In Recent Advances in Carbohydrate Engineering; Gilbert H. J.; Davies G. J.; Svensson, B.; Henrissat, B.; Eds. Royal Society of Chemistry, 1999, pp 3-12.
3. Davies, G. J.; Gloster, T. M.; Henrissat, B. Recent structural insights into the expanding world of carbohydrate-active enzymes. Curr. Opin. Struct. Biol. 2005, 15, 637-645.
4. Henrissat, B. A Classification of Glycosyl Hydrolases Based on Amino Acid Sequence Smilarities. Biochem. J. 1991, 280, 309-316.
5. Henrissat, B.; Bairoh, A. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem. J. 1993, 293, 781-788.
6. Chiba, S.; Hiromi, K.; Minamiura, N.; Ohnishi, M.; Shimomura, T.; Suga, K.; Suganuma, T.; Tanaka, A.; Tomioka, S.; Yamamoto, T. Quantitative study on anomeric forms of glucose produced by α-glucosidases. J. Biochem. 1979, 85, 1135-1141.
7. Chiba, S.; Kimura, A.; Matsui, H. Quantitative study of anomeric forms of glucose produced by α-glucosidases and glucoamylases. Agric. Biol. Chem. 1983, 47, 1741-1746.
8. Palcic, M. M.; Scaman, C. H.; Otter, A.; Szpacenko, A.; Romaniouk, A.; Li, Y. X.; Vijay, I. K. Processing α-glucosidase I is an inverting glycosidase. Glycoconj. J. 1999, 16, 351-355.
9. Hanozet, G.; Pircher, H.P.; Vanni, P.; Oesch, B.; Semenza, G. An example of enzyme hysteresis. The slow and tight interaction of some fully competitive inhibitors with small intestinal sucrase. J. Biol. Chem. 1981, 256, 3703-3711.
10. Zitzmann, N.; Mehta, A. S.; Carrouée, S.; Butters, T. D.; Platt, F. M.; McCauley, J.; Blumberg, B. S.; Dwek, R. A.; Block, T. M. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. USA 1999, 96, 11878-11882.
11. Seiichiro Ogawa, S.; Ashiura, M.; Uchida, C. Synthesis of α-glucosidase inhibitors: Kojibiose-type pseudodisaccharides and a related pseudotrisaccharide. Carbohydr. Res. 1998, 307, 83-95.
12. Nishio. T.; Miyake. Y.; Tsujii. H.; Hakamata. W.; Kadokura. K.; Oku. T. Hydrolytic activity of α-mannosidase against deoxy derivatives of p-nitrophenyl α-D-mannopyranoside. Biosci. Biotech. Biochem. 1996, 60, 2038-2042.
13. Hakamata. W.; Nishio. T.; Oku. T. Synthesis of p-nitrophenyl 3-and 6-deoxy-α-D-glucopyranosides and their specificity to rice α-glucosidase. J. Appl. Glycosci. 1999, 46, 459-463.
14. Hakamata, W.; Nishio, T.; Oku, T. Hydrolytic activity of α-galactosidase against deoxy derivatives of p-nitrophenyl α-D-galactopyranoside. Carbohydr. Res. 2000, 324, 107-115.
15. Hakamata, W.; Nishio, T.; Sato, R.; Mochizuki, T.; Tsuchiya, K.; Yasuda, M.; Oku, T. Synthesis of monomethyl derivatives of p-nitrophenyl α-D-gluco, galacto, and mannopyranosides and their hydrolytic properties against α-glycosidase. J. Carbohydr. Chem. 2000, 19, 359-377.
16. Nishio, T.; Hakamata, W.; Kimura, A.; Chiba, S.; Takatsuki, A.; Kawachi, R.; Oku, T. Glycon specificity profiling of α-glucosidases using monodeoxy and mono-O-methyl derivatives of p-nitrophenyl α-D-glucopyranoside. carbohydr. Res. 2003, 337, 629-634.
17. Hakamata, W.; Muroi, M.; Nishio, T.; Oku, T.; Takatsuki, A. Recognition properties of processing α-glucosidase I and α-glucosidase II. J. Carbohydr. Chem. 2004, 23, 27-39.
18. Nishio, T.; Hakamata, W.; Ogawa, M.; Nakajima, K.; Matsuishi, Y.; Kawachi, R.; Oku, T. Investigations of useful α-glycosidase for the enzymatic synthesis of rare sugar oligosaccharides. J. Appl. Glycosci. 2005, 52, 153-160.
19. Hakamata, W.; Muroi, M.; Kadokura, K.; Nishio, T.; Oku, T.; Kimura, A.; Chiba, S.; Takatsuki, A. Aglycon Specificity Profiling of α-Glucosidases Using Synthetic probes. Bioorg. Med. Chem. Lett. 2005, 15, 1489-1492.
20. Hakamata, W.; Muroi, M.; Nishio, T.; Oku, T.; Takatsuki, A.; Osada, H.; Fukuhara, K.; Okuda, H.; Kurihara, M. N-Linked Oligosaccharide Processing Enzymes as Molecular Targets for Drug Discovery. J. Appl. Glycosci. 2006, 53, 149-154.
21. Hakamata W. Yamamoto E.; Muroi M.; Mochizuki T.; Kurihara M.; Okuda H.; Fukuhara, K. Design and Synthesis of α-glucosidase inhibitor having DNA cleaving activity. J. Appl. Glycosci. 2006, 53, 255-260.
22. Caspary, W. F.; Graf, S. Inhibition of human intestinal α-glucosidehydrolases by a new complex oligosaccharide. Res. Exp. Med. 1979, 175, 1-6.
23. Kornfeld, R.; Kornfeld, S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 1985, 54, 631-664.
24. Killilea, T. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care. Am. J. Manag. Care 2002, 8, S441-S449.
25. Mitra, N.; Sinha, S.; Ramya, T. N.; Surolia, A. N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends. Biochem. Sci. 2006, 31, 156-163.
26. Bukau, B.; Weissman Horwich, A. Molecular chaperones and protein quality control. Cell 2006, 125, 443-451.
27. Hanefeld, M.; Fischer, S.; Schulze, J.; Spengler, M.; Wargenau, M.; Schollberg, K.; Fücker, K. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 1991, 14, 732-737.
28. Helenius, A.; Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 2004, 73, 1019-1049.
29. Ellgaard, L.; Helenius, A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 2003, 4, 181-91.
30. Helenius, A.; Aebi, M. Intracellular functions of N-linked glycans. Science 2001, 291, 2364-2369.
31. Ellgaard, L.; Molinari, M.; Helenius, A. Setting the standards: Quality control in the secretory pathway. Science 1999, 286, 1882-1888.
32. Suzuki, T.; Funakoshi, Y. Free N-linked oligosaccharide Chains: Formation and degradation. Glycoconj. J. 2006, 23, 291-302.
33. Meusser, B.; Hirsch, C.; Jarosch, E.; Sommer, T. ERAD: The long road to destruction. Nat. Cell Biol. 2005, 7, 766-772.
34. Lord, J.; Roberts, L.; Stirling, C. Quality control: Another player joins the ERAD cast. Curr. Biol. 2005, 15, R963-R964.
35. Yoshida, Y. A novel role for N-glycans in the ERAD system. J. Biochem. 2003, 134, 183-190.
36. Ma, Y.; Hendershot, L. M. The unfolding tale of the unfolded protein response. Cell 2001, 107, 827-830.
37. Schroder, M.; Kaufman, R. J. ER stress and the unfolded protein response. Mutat. Res. 2005, 569, 29-63.
38. Fiaux, H.; Popowycz, F.; Favre, S.; Schütz, C.; Vogel, P.; Gerber-Lemaire, S. Juillerat-Jeanneret, L. Functionalized pyrrolidines inhibit α-mannosidase activity and growth of human glioblastoma and melanoma cells. J. Med. Chem. 2005, 48, 4237-4246.
39. Van Den Elsen, J. M.; Kuntz, D. A.; Rose, D. R. Structure of golgi α-mannosidase II: A target for inhibition of growth and metastasis of cancer cells. EMBO J. 2001, 20, 3008-3017.
40. Dennis, J. M.; Granovsky, M.; Warren, C. E. Protein glycosylation in development and disease. Bioassays 1999, 21, 412-421.
41. Granovskya, M.; Warrena, C. E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1999, 1473, 21-34.
42. Pili, R.; Chang, J.; Partis, R. A.; Mueller, R. A.; Chrest, F. J.; Passaniti, A. The α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res. 1995, 55, 2920-2926.
43. Goss, P. E.; Baker, M. A.; Carver, J. P.; Dennis, J. W. Inhibitors of carbohydrate processing: A new class of anticancer agents. Clin. Cancer Res. 1995, 1, 935-944.
44. Atsumi, S.; Nosaka, C.; Ochi, Y.; Iinuma, H.; Umezawa, K. Inhibition of experimental metastasis by an α-glucosidase inhibitor, 1,6-Epi-cyclophellitol. Cancer Res. 1993, 53, 4896-4899.
45. De Clercq, E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 1995, 8, 200-239.
46. Robina, I.; Moreno-Vargas, A. J.; Carmona, A. T.; Vogel, P. Glycosidase inhibitors as potential HIV entry inhibitors? Curr. Drug Metab. 2004, 5, 329-361.
47. Naoki, A. Glycosidase inhibitors: Update and perspectives on practical use. Glycobiol. 2003, 13, 93R-104R.
48. Chapel, C.; Garcia, C.; Roingeard, P.; Zitzmann, N.; Dubuisson, J.; A. Dwek, R.: Trépo, C.; Zoulim, F.; Durantel, D. Antiviral effect of α-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. J. Gen. Virol. 2006, 87, 861-871.
49. Tong, S. Mechanism of HBV genome variability and replication of HBV mutants. J. Clin. Virol. 2005, 34, S134-138.
50. Saito, T.; Yamaguchi, I. Effect of glycosylation and glucose trimming inhibitors on the influenza a virus glycoproteins. J. Vet. Med. Sci. 2000, 62, 575-581.
51. Oostra, M.; de Haan, C. A. M.; de Groot, R. J.; Rottier, P. J. M. Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M. J. Virol. 2006, 80, 2326-2336.
52. Liang, P. H.; Cheng, W. C.; Lee, Y. L.; Yu, H. P.; Wu, Y.T.; Lin, Y. L.; Wong, C. H. Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: New structures for antivirals and osteoarthritis. Chembiochem. 2006, 7, 165-73.
53. De Clercq, E. Highlights in the development of new antiviral agents. Mini. Rev. Med. Chem. 2002, 2, 163-175.
54. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5, 876-885.
55. Fischer, U.; Schulze-Osthoff, K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005, 12, 942-961.
56. Yoshida, Y.; Chiba, T.; Tokunaga, F.; Kawasaki, H.; Iwai, K.; Suzuki, T.; Ito, Y.; Matsuoka, K.; Yoshida, M.; Tanaka, K.; Tai, T. E3 ubiquitin ligase that recognizes sugar chains. Nature 2002, 418, 438-442.
57. Lew, W.; Chen, X.; Kim, C.U. Discovery and development of GS 4104 (oseltamivir) an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 2000, 7, 663-672.
58. Dwek, R. A.; Butters, T. D.; Platt, F. M.; Zitzmann, N. Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 2002, 1, 65-75.
59. Bertozzi, C. R.; Kiessling, L. L. Chemical glycobiology. Science 2001, 291, 2357-2364.
60. Inouye, S.; Tsuruoka, T.; Nida, T. The structure of nojirimycin, a piperidinose sugar antibiotic. J. Antibiot. 1966, 19, 288-92.
61. Ishida, N.; Kumagai, K.; Niida, T.; Hamamoto, K.; Shomura, T. Nojirimycin, a new antibiotic. I. Taxonomy and fermentation. J. Antibiot. 1967, 20, 62-65.
62. Ishida, N.; Kumagai, K.; Niida, T.; Tsuroka, T.; Yumoto, H. Nojirimycin, a new antibiotic. II. Isolation, characterization and biological activity. J. Antibiot. 1967, 20, 66-71.
63. Inouye, S.; Tsuruoka, T.; Ito, T.; Niida, T. Structure and synthesis of nojirimycin. Tetrahedron 1968, 24, 2125-2144.
64. Legler, G. Glycoside hydrolases: Mechanistic information from studies with reversible and irreversible inhibitors. Adv. Carbohydr. Chem. Biochem. 1990, 48, 319-384.
65. Heightman, T. D.; Vasella, A. T. Recent insights into inhibition, structure, and mechanism of configuration-retaining glycosidases. Angew. Chem. Int. Ed. 1999, 38, 750-770.
66. Ganem, B. Inhibitors of carbohydrate-processing enzymes: Design and synthesis of sugar-shaped heterocycles. Acc. Chem. Res. 1996, 29, 340-370.
67. El Ashry, E. S. H.; Rashed, N.; Shobier, A. H. S. α-Glycosidase inhibitors and their chemotherapeutic value, Part 1. Pharamazie 2000, 55, 251-262.
68. El Ashry, E. S. H.; Rashed, N.; Shobier, A. H. S. α-Glycosidase inhibitors and their chemotherapeutic value, Part 2. Pharamazie 2000, 55, 331-348.
69. El Ashry, E. S. H.; Rashed, N.; Shobier, A. H. S. α-Glycosidase inhibitors and their chemotherapeutic value, Part 3. Pharamazie 2000, 55, 403-415.
70. Zechel, D. L.; Withers, S. G. Glycosidase mechanisms: Anatomy of a finely tuned catalyst. Acc. Chem. Res. 2000, 33, 11-18.
71. Asano, N.; Nash, R. J.; Molyneux, R. J.; Fleet, G. W. J. Sugarmimic glycosidase inhibitors: Natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron Asymmetry 2000, 11, 1645-1680.
72. Butters, T. D.; Dwek, R. A.; Platt, F. M. Chem. Rev. 2000, 100, 4683-4696.
73. Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R. J.; Nash, R. J. Phytochemistry 2001, 56, 265-295.
74. Nakao, Y.; Maki, T.; Matsunaga, S.; van Soest, R. W. M.; Fusetani, N. Penarolide sulfates A1 and A2, new α-glucosidase inhibitors from a marine sponge penares sp. Tetrahedron 2000, 56, 8977-8987.
75. Sou, S.; Mayumi, S.; Takahashi, H.; Yamasaki, R.; Kadoya, S.; Sodeoka, M.; Hashimoto, Y. Novel α-glucosidase inhibitors with a Tetrachlorophthalimide Skeleton. Bioorg. Med. Chem. Lett. 2000, 10, 1081-1084.
76. Hakamata, W.; Nakanishi, I.; Masuda, Y.; Shimizu, T.; Higuchi, H.; Nakamura, Y.; Saito, S.; Urano, S.; Oku, T.; Ozawa, T.; Ikota, N.; Miyata, N.; Okuda, H.; Fukuhara, K. Planar catechin analogues with alkyl side chains: A potent antioxidant and an α-glucosidase inhibitor. J. Am. Chem. Soc. 2006, 128, 6524-6525.
77. Kundu, B.; Rastogi, S.K.; Ahmad, R.; Srivastava, A.K. Identification of novel α-glucosidase inhibitors by screening libraries based on N-4-(benzyloxy) benzoyl alanine derivatives. Comb. Chem. High Throughput Screen 2002, 5, 545-550.
78. Zheng, W.; Padia, J.; Urban, D.J.; Jadhav, A.; Goker-Alpan, O.; Simeonov, A.; Goldin, E.; Auld, D.; LaMarca, M.E.; Inglese, J.; Austin, C.P.; Sidransky, E. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. USA 2007, 104, 13192-13197.
79. Tarling, C.A.; Woods, K.; Brastianos, H.C.; Zhang, R.; Brayer, G.D.; Andersen, R.J.; Withers, S.G. The search for novel human pancreatic α-amylase inhibitors: High-throughput screening of terrestrial and marine natural product extracts. ChemBiochem 2008, 9, 433-438.
80. Chiba, S. α-Glucosidase. In Handbook of Amylases & Related Enzymes; The Amylase Research Society of Japan; Eds.; Pergamon Press: Oxford, 1988; pp 104-116.
81. Chiba, S. Molecular mechanism in α-glucosidase and glucoamylase. Biosci. Biotechnol. Biochem. 1997, 61, 1233-1239.
82. Bause, E.; Schweden, J.; Gross, A.; Orthen, B. Purification and characterization of trimming glucosidase I from pig liver. Eur. J. Biochem. 1989, 183, 661-669.
83. Shailubhai, K.; Pratta, M. A.; Vijay, I. K. Purification and characterization of glucosidase I involved in N-linked glycoprotein processing in bovine mammary gland. Biochem. J. 1987, 247, 555-562.
84. Burns, D. M.; Touster, O. Purification and characterization of glucosidase II, an endoplasmic reticulum hydrolase involved in glycoprotein biosynthesis. J. Biol. Chem. 1982, 257, 9991-10000.
85. Frandsen, T. P.; Svensson, B. Plant α-glucosidase of the glycoside hydrolase family 31. Molecular properties, substrate specificity, reaction mechanism, and comparison with family members of different origin. Plant Mol. Biol. 1998, 37, 1-13.
86. Hino, Y.; Rothman, J. E. Glucosidase II, a glycoprotein of the endoplasmic reticulum membrane. Proteolytic cleavage into enzymatically active fragments. Biochemistry 1985, 24, 800-805.
87. Frandsen, T. P.; Lok, F.; Mirgorodskaya, E.; Roepstorff, P.; Svensson, B. Purification, enzymatic characterization, and nucleotide sequence of a high-isoelectric-point α-glucosidase from barley malt. Plant Physiol. 2000, 123, 275-286.
88. Kita, A.; Matsui, H.; Somoto, A.; Kimura, A.; Takata, M.; Chiba, S. Substrate specificity and subsite affinities of crystalline α-glucosidase from Aspergillus niger. Agric. Biol Chem. 1991, 55, 2327-2335.
89. Shailubhai, K.; Pratta, M. A.; Vijay, I. K. Purification and characterization of glucosidase I involved in N-linked glycoprotein processing in bovine mammary gland. Biochem. J. 1987, 247, 555-562.
90. Kaushal, G. P.; Elbein, A. D. Glycosidase inhibitor in study of glycoconjugates. Meth. Enzymol. 1994, 230, 316-329.
91. Tsujii, E.; Muroi, M.; Shiragami, N.; Takatsuki, A. Nectrisine is a potent inhibitor of α-glucosidases, demonstrating activities similarly at enzyme and cellular levels. Biophys. Biophys. Res. Commun. 1996, 220, 459-466.
92. Bajorath, J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. 2002, 1, 882-894.
93. Steven, P.; David, J. E.; Remy, H. Challenges of target/compound data integration from disease to chemistry: A case study of dihydrofolate reductase inhibitors. Curr. Drug Discov. Technol. 2005, 2, 75-87.
94. Martin, S. Current status of virtual screening as analyzed by target class. J. Med. Chem. 2006, 2, 89-112.
95. Ernsta, H. A.; Leggioa, L. L.; Willemoësa, M.; Leonardc, G.; Blumd, P.; Larsena, S. Sructure of the Sulfolobus solfataricus α-glucosidase: Implications for domain conservation and substrate recognition in GH31. J. Mol. Biol. 2006, 358, 1106-1124.
96. Lovering, A.L.; Lee, S.S.; Kim, Y.W.; Withers, S.G.; Strynadka, N.C. Mechanistic and structural analysis of a family 31 α-glycosidase and Its glycosyl-enzyme intermediate J. Biol. Chem. 2005, 280, 2105-2115.
97. PDB ID: 1WE5, Crystal structure of α-xylosidase from Escherichia coli, To be published.
98. Kim, Y.-W.; Lovering, A. L.; Chen, H.; Kantner, T.; McIntosh, L. P.; Strynadka, N. C. J.; Withers, S. G. Expanding the thioglycoligase strategy to the synthesis of α-linked thioglycosides allows structural investigation of the parent enzyme/substrate complex. J. Am. Chem. Soc. 2006, 128, 2202-2203.
99. Okuyama, M.; Kaneko, A.; Mori, H.; Chiba, S.; Kimura, A. Structural elements to convert Escherichia coli α-xylosidase (YicI) into α-glucosidase. FEBS Lett. 2006, 580, 2707-2711.
100. Okuyama, M.; Kang, M.; Yaoi, K.; Mitsuishi, Y.; Mori, H.; Kimura, A. Substrate recognition of Escherichia coli YicI (α-xylosidase). J. Appl. Glycosci. 2008, 55, 111-118.
101. Watanabe, K.; Hata, Y.; Kizaki, H.; Katsube, Y.; Suzuki, Y. The refined crystal structure of Bacillus cereus Oligo-1,6-glucosidase at 2.0 Å resolution: Structural characterization of proline-substitution sites for protein thermostabilization. J. Mol. Biol. 1997, 269, 142-153.
102. MOE software available from Chemical Computing Inc., Montreal Canada. Consult http://www.chemcomp.com for further information.
103. von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Van Phan, T.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-423.
104. Itzstein, M.; Wu, W.-Y.; Jina, B. The Synthesis of 2,3-Didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: A potent influenza virus sialidase inhibitor. Carbohydr. Res. 1994, 259, 301-305.
105. Alymova, I. V.; Taylor, G. Portner, A neuraminidase inhibitors as antiviral agents. Curr. Drug Targets-Infect. Disord. 2005, 5, 401-409.
106. Mann, M. C.; Islam, T.; Dyason, J. C.; Florio, P.; Trower, C. J.; Thomson, R. J.; Itzstein, M. Unsaturated N-acetyl-D-glucosaminuronic acid glycosides as inhibitors of influenza virus sialidase. Glycoconj. J. 2006, 23, 127-133.
107. Wei, D. Q.; Du, Q. S.; Sun, H.; Chou, K. C. Insights from Modeling the 3D Structure of H5N1 Influenza Virus Neuraminidase and Its Binding Interactions with Ligands. Biochem. Biophys. Res. Commun. 2006, 344, 1048-1055.
108. Park, H.; Hwang, K.Y.; Oh, K.H.; Kim, Y.H.; Lee, J.Y.; Kim, K. Discovery of novel α-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. Bioorg. Med. Chem. Lett. 2008, 16, 284-292.
109. Park, H.; Hwang, K. Y.; Kim, Y.H.; Oh, K.H.; Lee, J.Y.; Kim, K. Discovery and biological evaluation of novel α-glucosidase inhibitors with in vivo antidiabetic effect. Bioorg. Med. Chem. Lett. 2008, 18, 3711-3715.
110. Bharatham, K.; Bharatham, N.; Park, K.H.; Lee, K.W. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of α-glucosidase inhibitors. J. Mol. Graph Model. 2008, 26, 1202-1212.
111. Molegro software available from BiRC - Bioinformatics Research Center, Denmark. Consult http://www.molegro.com/ for further information.
112. Accelrys Discovery Studio available from Accelrys, Inc., San Diego, CA, USA. Consult http://www.accelrys.com/ for further information.